Jamie Rich

Company: Zymeworks

Job title: Senior Director, Technology, ADC Therapeutics Group

Seminars:

Improvements to Leading ADC Platform Technologies? 6:00 pm

• Explaining how antibody-linker stabilisation impacts the dosing, safety, and pharmacokinetics of vedotin ADCs • Investigating diverse approaches to improvement of deruxtecan ADCs • Forecasting validation of ADC philosophy impact in clinical trialsRead more

day: Conference Day One pt 2